Cancer vaccine strategies get bigger and better

Nature Medicine

Volumn 5, Issue 10, 1999, Pages 1124-1125

  De Gruijl, Tanja D ^a   Curiel, David T ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

ACTIVE IMMUNIZATION; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CLINICAL PROTOCOL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOREGULATION; LYMPHOMA; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; CYTOTOXICITY, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR;

EID: 0032825216     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/13443     Document Type: Short Survey

References (11)

1. Rosenberg, S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287 (1999).
2. Vermorken, J.B. et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet 353, 345-350 (1999).
3. Nestle, F.O. et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med. 2, 52-58 (1998).
4. Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52-58 (1996).
5. Rosenberg, S.A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327 (1998).
6. Pardoll, D.M. Cancer vaccines. Nature Med. (suppl.) 4, 525-531 (1998).
7. Bendandi, et al. Molecular complete remissions induced by patient-specific vaccination plus GM-CSF against lymphoma. Nature Med. 5, 1171-1177 (1999).
8. Levitsky, H.I. et. al. Immunization with granulecyte-macrophage colony stimulating factor-transduced, but not 87.1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol. 156, 3858-3865 (1996).
9. Nelson, E.I. et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88, 580-589 (1996).
10. Mackey, M.F. et al. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol. 161, 2094-2098 (1998).
11. French, R.R. et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nature Med. 5, 548-553 (1999).